PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
Abstract Introduction Hotspots (HS) mutations in the PIK3CA gene may lead to poorer oncological outcomes and endocrine resistance in advanced breast cancer (BC), but their prognostic role in early‐stage disease remains controversial. The overall agreement within plasma and tissue methods has not bee...
Saved in:
Main Authors: | Eduardo Terán, Rebeca Lozano, César A. Rodríguez, Mar Abad, Luis Figuero, José Antonio Muñoz, Belén Cigarral, Aline Rodrígues, Magdalena Sancho, M. Asunción Gómez, Daniel Morchón, Juan Carlos Montero, José María Sayagués, M. Dolores Ludeña, Emilio Fonseca |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.70101 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of PIK3CA somatic mutations with clinicopathological parameters in breast cancer
by: Gizem Teoman, et al.
Published: (2024-12-01) -
CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01) -
Predicting breast cancer prognosis using PR and PIK3CA biomarkers: a comparative analysis of diagnostic groups
by: Yuting Feng, et al.
Published: (2025-01-01) -
Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
by: Ram Patel, et al.
Published: (2025-01-01) -
Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer
by: Ming-Jing Lee, et al.
Published: (2023-04-01)